Neuren profit falls on absence of one-offs as core royalties and R&D spend climb

Neuren Pharmaceuticals Limited ( (AU:NEU) ) has issued an update.

Neuren Pharmaceuticals reported a sharp fall in reported revenue and profit for 2025, reflecting the absence of large one-off payments booked in the prior year, even as its core royalty stream and interest income continued to grow. Total revenue from ordinary activities dropped 63% to A$84.8 million and net profit slid 79% to A$30.4 million, but recurring royalty income from Acadia’s DAYBUE rose 15% to A$64.6 million and finance income also increased.

The company lifted research and development spending to A$36.4 million, driven by the start-up of a Phase 3 trial of NNZ-2591 in Phelan-McDermid syndrome, while corporate and administrative costs rose on higher share-based payments. Neuren booked an A$3.3 million loss on forward currency contracts but benefited from an A$8.0 million foreign exchange gain on cash holdings, executed A$39.6 million of on-market share buy-backs instead of paying dividends, and ended the year with net tangible assets of 258.90 cents per share, down from 273.52 cents.

The most recent analyst rating on (AU:NEU) stock is a Buy with a A$27.00 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.

More about Neuren Pharmaceuticals Limited

Neuren Pharmaceuticals Limited is a biopharmaceutical company focused on developing therapies for serious neurological disorders, including rare and pediatric conditions. Its portfolio includes NNZ-2591, now in a Phase 3 trial for Phelan-McDermid syndrome, and it earns royalty income from DAYBUE sales through a licensing agreement with U.S. partner Acadia.

Average Trading Volume: 367,864

Technical Sentiment Signal: Sell

Current Market Cap: A$1.55B

Learn more about NEU stock on TipRanks’ Stock Analysis page.